Abstract: Some embodiments of the invention provide a suspension system coupled to a main frame of ride-on equipment including a subframe coupled to the main frame with a pivot including a pivot axis. Some embodiments include a transaxle assembly supported on the subframe coupled to a drive wheel, and a power source supported on the main frame coupled to the transaxle assembly. A rider can control the transaxle assembly with a compensated control linkage assembly that can compensate for movement of the subframe. Some embodiments include driven pulleys, idler pulleys and backside idler pulleys supported by the subframe coupled to the power source not supported by the subframe. In some embodiments, the pivot axis resides between the power source and the transaxle assembly. In some embodiments, the drive wheel can be driven by an electric motor supported by the subframe and the power source can be a battery.

Abstract: The present invention provides methods for treating and/or preventing conditions and diseases in humans and other mammals that are associated with and/or mediated by signal transduction pathways comprising platelet-derived growth factor receptor (PDGFR) by administering diaryl ureas of Formula I. The present invention also provides devices and methods for treating, ameliorating, preventing, or modulating restenosis following angioplastic surgery or other invasive procedures that affect or injure the vascular system, and graft rejection following transplantation of a donor tissue into a host, where a stent or other omplantable device comprises an effective amount of diaryl ureas of Formula I.

Abstract: Systems and methods can be used to reduce power consumption on a device. In some implementations, power consumption can be reduced by powering down modules. In other implementations, power consumption can be reduced by communicating configuration status messages to the terminating system to reduce communications. Power saving can extend backup battery power duration thereby affording users to access telephone services during a power outage.

Abstract: Methods for automatically providing a backup license for a device that relies on a primary license to operate when the primary license for the device fails to satisfy a licensing requirement are provided. A backup license that can become automatically available for use upon noncompliance of a primary license can prevent service interruptions, which are unacceptable for systems that provide continuous service and require high reliability. For example, methods of the disclosure can be used in cable systems and more specifically in cable modem termination systems to prevent an interruption in service.

Abstract: Disclosed are compounds and derivatives thereof, their synthesis, and their use as Rho-kinase inhibitors. These compounds of the present invention are useful for inhibiting tumor growth, treating erectile dysfunction, and treating other indications mediated by Rho-kinase, e.g., coronary heart disease.

Abstract: Disclosed are compounds and derivatives thereof, their synthesis, and their use as Rho-kinase inhibitors. These compounds of the present invention are useful for inhibiting tumor growth, treating erectile dysfunction, and treating other indications mediated by Rho-kinase, e.g., coronary heart disease.

Abstract: A process for the preparation of various quinazoline compounds which are useful as Rho-Kinase inhibitors, and thus having utility in the treatment of hypertension and other indications.

Abstract: Disclosed are compounds and derivatives thereof their synthesis, and their use as Rho-kinase inhibitors. These compounds of the present invention are useful for inhibiting tumor growth, treating erectile dysfunction, and treating other indications mediated by Rho-kinase, e.g., coronary heart disease.

Abstract: A process for the preparation of various quinazoline compounds which are useful as Rho-Kinase inhibitors, and thus having utility in the treatment of hypertension and other indications.

Abstract: A platform (1) allows end users to engage in a session with servers such as content providers, corporate systems, commercial services or ASPs. A session object is associated with each session, attributes of which include the channel—thereby allowing changing of a channel during a session. Request/event objects are associated with the session object as requests/notifications arise, and these objects are shared with other modules. Hosted services may be physically resident on the platform or may be accessed transparently via interfaces. A device/channel neutral mark-up language extended from a presentation mark-up language is used as a single common form from which the delivered content is derived. The content from a service is generated by an executable process, normally (but not exclusively) in the extended mark-up language. The derivation of deliverable content is performed via a dynamic and configurable sequence of providers that manipulate the original content in stages.

Abstract: Disclosed are compounds and derivatives thereof their synthesis, and their use as Rho-kinase inhibitors. These compounds of the present invention are useful for inhibiting tumor growth, treating erectile dysfunction, and treating other indications mediated by Rho-kinase, e.g., coronary heart disease.

Abstract: An expandable ambulatory walking device and method of use are disclosed. In one form, an ambulatory walking device includes an elongated member having a first end and a second end and a rubber contact material coupled to the first end. The device further includes an expandable handle coupled a second end of the elongated member and operable to be provided in a collapsed state providing a handle. The expandable handle is also operable to be provided in an expanded state to provide a seat for the user.

Abstract: The present invention provides methods of using aryl ureas to treat diseases and conditions associated with signal transduction pathways comprising at least one of raf, VEGFR, PDGFR, p38 and/or FLT-3. The present invention also provides compositions and methods for identifying conditions and diseases which can be modulated with compounds of the present invention. These methods facilitate the selection of subjects who can be efficiently treated with compounds of the present invention. Additionally, the invention provides methods for monitoring subjects who have been administered a compound of the present invention.

Abstract: Disclosed are compounds and derivatives thereof, their synthesis, and their use as Rho-kinase inhibitors. These compounds of the present invention are useful for inhibiting tumor growth, treating erectile dysfunction, and treating other indications mediated by Rho-kinase, e.g., coronary heart disease.

Abstract: A method and apparatus for electrically connecting a die to a package while reducing the length of wirebonds. This in turn reduces wire-sweep and the cost of manufacture. To reduce the length of the wirebonds, bonding holes are created through an insulating layer of the package to expose a conductive layer. A wirebond connects through the bonding hole to a conductive layer that is exposed by the hole. The attachment point for the wirebond on the conductive layer may be prepared to serve as a bonding pad. Using this technique the prior art method utilized a bonding pad on the top surface of the inner surface of the package, which electrically connects through a trace to a via, which in turn electrically connects to a conductive layer may be avoided thereby allowing for closer spacing of radially concentric rows of attachment points on the package around the die.

Abstract: A method and apparatus for testing a package design and material set comprising using a test die to form a test device and subjecting the test device to a test procedure, such as a highly accelerated stress test (HAST). In one embodiment the device, which comprises a die and a package to be tested, is constructed using a test die. The test die comprises a non-functional die having one or more conductive traces thereon. Use of a test die reduces costs as compared to a functional die and reduces the time to market by allowing package testing prior to creation and testing of a functional die. In one embodiment the test die is configure with conductive traces on its top surface to allow for biasing before, during, or after testing.

Abstract: The present invention provides methods for treating and/or preventing conditions and diseases in humans and other mammals that are associated with and/or mediated by signal transduction pathways comprising platelet-derived growth factor receptor (PDGFR) by administering diaryl ureas of Formula I. The present invention also provides devices and methods for treating, ameliorating, preventing, or modulating restenosis following angioplastic surgery or other invasive procedures that affect or injure the vascular system, and graft rejection following transplantation of a donor tissue into a host, where a stent or other omplantable device comprises an effective amount of diaryl ureas of Formula I.

Abstract: The present invention provides methods for inducing apoptosis in a cell, the methods generally involving contacting the cell with an agent that reduces the level and/or activity of RabGGT. The present invention further provides methods for treating a disorder related to unwanted cell proliferation in an individual, the methods generally involving administering to the individual an agent that reduces the level and/or activity of RabGGT. The present invention further provides methods for reducing apoptosis in a cell, the methods generally involving increasing the level and/or activity of RabGGT in the cell. The present invention further provides methods for treating disorders associated with excessive apoptosis. The present invention further provides methods for identifying a cell that is amenable to treatment with the methods of the present invention. The present invention further provides methods for modulating a binding event between RabGGT and a RabGGT interacting protein.

Abstract: Disclosed are compounds and derivatives thereof, their synthesis, and their use as Rho-kinase inhibitors. These compounds of the present invention are useful for inhibiting tumor growth, treating erectile dysfunction, and treating other indications mediated by Rho-kinase, e.g., coronary heart disease.

Abstract: A process for the preparation of various quinazoline compounds which are useful as Rho-Kinase inhibitors, and thus having utility in the treatment of hypertension and other indications.